Xueyan Zhang

Years Active: 2020-2021
Publications (10 Years): 2

This page only lists publications with an associated author ORCID identifier.

Publications

Changhui Li, Wei Nie, Jingdong Guo, Anning Xiong, Hua Zhong, Tianqing Chu, Runbo Zhong, Jianlin Xu, Jun Lu, Xiaoxuan Zheng, Bo Zhang, Yinchen Shen, Feng Pan, Baohui Han, Xueyan Zhang
Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation. Respiratory research 22 (1) (2021)
Hai Zhang, Xiaohua Yang, Fang Hu, Changhui Li, Jianlin Xu, Wei Nie, Yinchen Shen, Yuqing Lou, Baohui Han, Hua Zhong, Xueyan Zhang
Expression Level of Wnt5a Was Related to the Therapeutic Effects of First-Generation EGFR-TKIs. OncoTargets and therapy 13 (2020)

Xueyan Zhang.css-eqlu8i{font-size:small;padding-left:4px;}